Human chorionic gonadotrophin (hCG) was first described in 1920 by Hirose! while studying corpus luteum formation in the rabbit. Since then, application of its measurement in the diagnosis and monitoring of pregnancy has become universal1y accepted. hCG is a wel1established marker for choriocarcinoma-and is also becoming increasingly important as a tumour marker in other malignancies and, more recently, as a marker of fetal abnormalities. With the continuing elucidation of the structure and function of the parent hCG molecule and its subunits and fragments, the utility of measurement of hCG and hCG-related species, both in serum and urine, is likely to increase. Excellent reviews have described the molecular biology of hCG,3 recent advances in the understanding of immunochemical aspects of clinically significant forms of hCG,4.5 and the impact of these advances on its clinical measurement."
These developments have been stimulated in part by progress in the analytical methods available for measurement of hCG. Further desirable improvements in the immunochemical determination of hCG, and in the standardization of hCG measurements, were considered at the 4th Bergmeyer Conference in 1992, and detailed recommendations have subsequently been published.' The Canadian Society of Clinical Chemists has also published a position paper considering broad issues of standardization of polypeptide hormone measurements, including hCG. This review will primarily address methodological aspects of hCG measurement, highlighting changes since these were last reviewed in this journal.!" and bringing together practical information of relevance to laboratories providing an analytical service including hCG measurement. Where possible, reference will be made to the recommendations in the Bergmeyer report."
STRUCTURE AND NOMENCLATURE OF hCG AND RELATED MOLECULES
hCG belongs to the family of glycoprotein hormones which includes human luteinizing hormone (hLH), human follicle stimulating hormone (hFSH) and human thyroid stimulating hormone (hTSH). The four molecules are heterodimers, sharing a commona-subunit but differing in their (i-subunits, which confer immunological and functional specificity. The (i-subunit of hCG shares considerable homology with that of hLH, but possesses an additional 32 amino acid carboxy-terminal extension.
The crystal structure of hCG has now been described. I I Each of the two subunits has a similar topology, with three disulphide bonds forming a cystine knot, a similar arrangement to that found in some protein growth factors, such as transforming growth factor-If (TGF-fJ) and platelet-derived growth factor-(i (PDGF-fJ). Stabilizing the heterodimer, a segment of the (isubunit wraps around the o-subunir. covalently linked by a seat belt-like loop. This spatial arrangement appears to be essential both for the association of the :x-and If-subunits and for glycoprotein receptor binding. Knowledge of the detailed structure of hCG, which permits precise identification of the relative locations of regions on the hormone's surface, should facilitate epitope mapping and hence future development of improved methods for hCG measurement.'? 'This nomenclature is broadly similar to that recommended in the National Committee for Clinical laboratory Standards (NCClS) report.? although its authors recommend use of 'CG dimer' when referring to the intact hCG molecule and caution that the term 'intact' hCG may be misleading, as it implies not only the dimeric form but also the absence of any peptide nicks or carbohydrate modifications. The NCClS report recommends glycoprotein hormone alpha (i.e. GPH~) as common terminology for the z-subunits of hCG, thyroid stimulating hormone (TSH), luteinizing hormone (lH) and follicle stimulating hormone (FSH), but comments that use of hCG~, as recommended by the International Federation of Clinical Chemistry? may be preferable in certain circumstances, because post-translational modifications probably differ, depending on which hormone the subunit resides in.
:Also sometimes referred to as urinary gonadotrophin peptide (UGP), but UGP is often used to denote a more diffuse entity than hCG/1cf. In biological fluids, hCG-like molecules may exist as intact heterodimeric hCG, as modified hCG (for example, 'nicked' hCG, hCGn), as its free subunits (ex and f3) or as degradation products (for example, {i-core fragment, hCGpcf). 13 [hCG{icf is occasionally and somewhat misleadingly referred to as urinary gonadotrophin peptide (UGP), but UGP may also be used to denote a more diffuse moiety than hCG/kf, which is a chemically defined structure.]
The lack of a universally adopted nomenclature causes confusion in the literature. In an attempt to clarify this, the relationship between these molecules, together with previously recommended nomenclature" which will be used in this review, is shown in Table I (refs 14---16) . When considering hCG methods, it is desirable to group them according to which hCG-related species they measure, insofar as this information is available. Commercially available methods can be broadly classified as measuring predominantly hCG ('intact' methods), hCG + hCGfJ ('total' methods), hCGex, hCGfJ, or hCGpcf, and the requisite immunoassay formats are depicted schematically in Fig. I . This broad classification does not take account of structural modifications that may occur (for example, nicking of the polypeptide chain, and amino acid or carbo-hydrate heterogeneity), because there is as yet very little information available about how commercial methods recognize these variants, or, indeed, of their clinical significance. A list of most commercially available immunoassay methods for hCG determination is conveniently available in the Kluwer Immunoassay Directoryl! which provides very helpful information that has been extracted from kit inserts.
CLINICAL REASONS FOR REQUESTS FOR hCG MEASUREMENTS
The clinical requirements for measurement of hCG are summarized in Tables 2 and 3 and are described in greater detail below.
Measurement of hCG in healthy men and non-pregnant women
Concentrations of hCG can be measured in the serum and urine of healthy men and nonpregnant women when highly sensitive assay methods are used. Gonadal function influences hCG concentration: in women, the upper reference limit for hCG using one method has been reported to increase from 3 to 5 U/L (serum) and from 3 to 4 U/L (urine) in postmenopausal women.l" Similarly, upper reference :... TABLE 2. Requirements of human chorionic gonadotrophin (hCG) methods in pregnancy .,. § 0\ .,. 
Measurement of bCG in pregnancy
Requests for hCG measurement received in a routine laboratory will be predominantly for the diagnosis and monitoring of pregnancy and fall into six main categories ( Table 2) . Ectopic pregnancy hCG measurements contribute significantly to the diagnosis and management of ectopic
Early pregnancy monitoring
Quantitative measurement of hCG is also very helpful when investigating a woman presenting with abdominal symptoms and/or vaginal bleeding which mayor may not be associated with pregnancy. Provided the method has good analytical sensitivity (hCG < 25 U/L), urine pregnancy tests are positive in 95% of patients with ectopic pregnancy, and there are few false negatives.P If the pregnancy test is positive, subsequent quantitative monitoring of serum hCG, in association with ultrasound, is particularly helpful in assessing patients with a history of ectopic pregnancy or early miscarriage. The gestational age and serum hCG concentration at which a viable intrauterine pregnancy can be detected by ultrasound will depend both on the hCG method used and on the local ultrasound facilities and expertise. However, if the serum hCG concentration exceeds about 1000 U/L, an intrauterine sac should be visible by vaginal ultrasonography in an intrauterine pregnancy: its absence strongly suggests an ectopic pregnancy.i" A serum hCG decreasing with a half-life of 12h to 2 days can be used to identify complete or missed abortions, while a persistently detectable hCG following miscarriage or laparoscopic removal of the products of conception suggests incomplete removal of tissue and requires further investigation. It should be noted that, following abortion in the first trimester, it may take as long as 60 days for hCG concentrations to return to within the reference range from the very high values present at 7-10 weeks. 25 tion following treatment for infertility, to investigate otherwise unexplained amenorrhoea, or to exclude pregnancy when procedures which could injure a fetus are being considered. Qualitative testing based on the detection of hCG in urine is usually sufficient: a positive test confirms pregnancy, while a negative test (with a cut-off concentration of 20-50 U/L) usually excludes ectopic pregnancy." However, quantitative measurement of serum hCG and demonstration of an appropriate hCG doubling time may be required to assess whether the pregnancy is normal or not. The performance of a number of visually read pregnancy tests has recently been assessed. 21 
Routine pregnancy diagnosis or exclusion of pregnancy
In pregnancy, hCG is produced in large amounts by the syncytiotrophoblasts of the placenta, and an increase in serum hCG can usually be detected when implantation occurs, 7-9 days after conception (or 22-24 days after the last menstrual period in a normal 28-day cycle). Serum hCG concentrations increase at an exponential rate, with a doubling time of up to 2 days for the first 5 to 6 weeks, reaching peak concentrations of approximately 100 000 U/L at 7-10 weeks of pregnancy'? ( Fig. 2 ). The concentrations then decrease about IO-fold before reaching a plateau and remaining relatively constant until near to term, when they increase slightly before rapidly falling to within the reference range postpartum. The complex kinetics of disappearance of serum hCG, hCGtx and hCGp following delivery have recently been investigated.P Pregnancy testing is usually performed to confirm the clinical signs and symptoms of pregnancy, to allow early detection of implanta-limits for men under 50 years are reported to be 0·7 U/L (serum) and I U/L (urine), increasing to 2 U/L (serum) and 3 U/L (urine) in older men. It is important to recognize that hCG concentrations of up to 8-10 U/L in healthy women and 3--4U/L in healthy men may occasionally be observed. 18 pregnancy.P-" A number of studies have demonstrated that measurement of serial hCG concentrations in suspected ectopic pregnancy can significantly reduce the number of laparoscopic interventions, as some ectopic pregnancies will abort spontaneously and may not require surgical intervention, with its possible adverse effects on future fertility. If serum hCG is relatively low « 1000U/L,25.2x <2000U/U 9 and < 2500 U/L]o.]! are cut-off concentrations which have been suggested) and decreasing, conservative management, or possibly treatment with methotrexate, ]2.]] is frequently successful; monitoring of serum hCG at 2-3 day intervals is then essential. 29 It has been suggested that a sliding scale approach to prescribing methotrexate, based on the initial serum concentration of hCG, may be therapeutically efficacious.P For women who have had one ectopic pregnancy and are consequently at increased risk of another, close monitoring during the first 5-8 weeks of pregnancy is desirable, as this allows early diagnosis before symptoms appear, and allows safe and effective non-surgical treatrnent.l?
Screening for Down 's syndrome (fetal trisomy 2/) Accurate measurement of hCG or hCGp, makes an important contribution to the panel of tests for pre-natal screening for Down's syndrome." Most laboratories combine hCG determination with measurement of rx-fetoprotein (AFP) and/or unconjugated oestriol, also taking maternal age into account in order to arrive at an assessment of risk. Screening policy in a number of centres has recently been reviewed." While some workers suggest that hCGp and AFP may provide the best cornbination.V and others dispute the superiority of hCGp over intact hCG,]K all current screening programmes include one or other of these analytes. Promising results have recently been obtained using hCGpcr, urinary concentrations of which show much larger increases in Down's syndrome pregnancies than do hCGfJ concentrations in blood. 39 ,4O 
Benign gestational trophoblastic disease (hydatidiform mole)
The presence of hydatidiform mole, an abnormal conceptus from which an embryo either never develops or is reabsorbed early, is now usually identified by ultrasound and confirmed by histopathology. However, it is
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important to measure serum hCG concentrations, which are equal to or greater than those seen in normal pregnancies of similar gestation, before evacuation of a suspected mole, and fortnightly thereafter until the concentrations return to normal. Serial measurements can be helpful in differentiating molar from normal pregnancies, since hCG concentrations in molar pregnancies do not peak in the first trimester but continue to increase in proportion to the increasing mass of the trophoblast. Greater molecular heterogeneity of hCG occurs in trophoblastic than in normal pregnancies, as maternal serum samples from trophoblastic pregnancies contain varying mixtures of hCG and uncombined and degraded moelcules (e.g, hCGn, hCGn missing p-C-terminal peptide, hCGP). 41 Since different types of immunoassay configuration will yield disparate results, it is particularly important that the same method be used for serial measurements. All patients in the United Kingdom should be registered with the National Hydatidiform Mole Registry42,4] since up to 10% of patients registered each year may require chemotherapy for invasive mole or choriocarcinoma.
Detection of retained products of conception
Serial monitoring of serum hCG concentrations following surgical or medical management of ectopic pregnancy, surgical removal of a molar pregnancy, or spontaneous or induced abortion may be helpful in establishing complete elimination of trophoblastic tissue. 44, 45 It should be noted that the rate of clearance is not rapid and is variable among patients. Elimination is probably initially exponential, with a half-life of a day or less, but slowing later to a half-life of several days. As the highly sensitive hCG assays now in use may detect concentrations in serum for several weeks, caution must be exercised before concluding that there are retained products of conception.
Measurement of hCG in malignancy
The testicular and germ cell malignancies for which hCG is a well-established tumour marker (Table 3) are relatively rare, but the high clinical specificity of the marker, together with the availability of very effective therapy, makes its measurement (together with that of AFP) integral to successful patient management." Use of hCG and hCGp measurements in these and other malignancies has recently been reviewed." Measurement of urinary degradation products ofhCG, such as hCG{Jcf, may also find clinical application, particularly in bladder and gynaecological malignancies." As with all other tumour markers, it is the trend in marker concentration (and the rate of increase or decrease from baseline pre-treatment concentrations), rather than the absolute marker concentration at any given time, that is likely to be most informative.
Malignant trophoblastic disease (choriocarcinoma)
Relapse of trophoblastic tumours, which frequently indicates development of malignant disease (i.e. choriocarcinoma), is readily detectable by measurement of hCG and hCG{J. Clinical specificity is high, partly because hCG concentrations in non-pregnant women are very low, and partly because production of hCG by trophoblast tissue is extremely high: 10 7 choriocarcinoma cells produce enough hCG to increase measured serum concentrations." Simultaneous measurement of hCG and hCGf1 allows differentiation between benign and malignant disease at presentation, as an hCG[1:hCG ratio greater than 5% (when calculated on the basis of molar concentrations) specifically indicates chorionic malignancy. 50
The ratio is generally lowest in hydatidiform mole, intermediate in invasive mole, and highest in choriocarcinoma. The advantages of this approach for diagnosis, prognosis and followup, have been reviewed? and it is likely to be increasingly adopted as assays for hCG/1 become better standardized and more widely available. Long-term follow-up of patients who have had malignant trophoblastic disease is very important, and can be well organized, sometimes on a national basis, as has been achieved in the United KingdomY
Testicular cancer hCG and AFP are important tumour markers in testicular cancers, contributing to the diagnosis, prognosis and long term follow-up in patients with these malignancies, as well as providing highly effective indicators of the success of therapy during treatment. Both markers are elevated in 40-60% of all non-seminomatous testicular cancers, and either may be elevated in up to 90% of cases." These tumours may produce hCG, hCG and hCG/1, or, occasionally, only hCG{J.51 hCG/1 is also produced by seminomas, fewer than 20% of which produce hCG.46 hCGrx may also be elevated in about
Ann Clin Biochem 1998: 35 10-20% of patients with testicular cancer.V Scottish Guidelines concerning the management of testicular germ cell tumours, and including recommendations about the appropriate use of tumour markers, are currently being prepared.V and similar guidelines are likely to be prepared elsewhere.
Ovarian germ cell tumours hCG and AFP are also the most useful markers in these tumours, which account for fewer than 5% of all ovarian malignancies. Measurement of hCG and hCGf1 is most important for the majority of these tumours (including dysgerminomas and choriocarcinomas), although teratomas may also produce AFP. Yolk sac (endodermal sinus) tumours only produce AFP. Appropriate clinical applications are similar to those for testicular tumours.
Non-trophoblastic tumours hCG may occasionally be elevated in a variety of non-trophoblastic tumours, but its lack of clinical specificity and the relative infrequency of its elevation limit its usefulness. However, recent reports suggest that measurement ofhCGff in serurrr" and hCGffef in urinc'" may be useful markers for many other non-trophoblastic tumours. These include cancer of the bladder, lung, pancreas, hepatobiliary tract, and gastrointestinal tract,52.55.56 and it is important to remember that such ectopic production may account for unexpected elevations in serum hCG concentrations. The ultimate clinical utility of serum hCGf1 or urinary hCGficf measurements remains to be determined, and will first require improvements in both methodology and assay standardizatiorr'V':" but it seems likely that these markers may contribute effectively to patient management, particularly in bladder cancer for which no good serum markers arc yet available.
Other applications for hCG measurement
Abuse of hCG in sport has become popular because hCG stimulates the secretion from the testes of both testosterone and epi-testosterone; production of the latter masks testosterone and complicates detection of excess testosterone by drug testing authorities.t" For discussion of the complex issues relating to this rather specialized subject. the reader is referred to two recent reviews.P'':"' The need for forensic confirmation of the presence of hCG in cases of suspected misuse for performance enhancement has led to investigation of the potential of high performance liquid chromatography/mass spectrometric techniques for characterizing hCG and its metabolites.F These techniques may also be useful for the characterization of candidate reference materials.
Implications of clinical applications for hCG assay requirements
The numerous clinical applications for hCG measurements (Tables 2 and 3 ) illustrate the varied req uirements for provision of a diagnostic service for hCG. For maternal screening, a rapid assay with a broad working range is desirable and simultaneous measurement of AFP is often advantageous. For tumour marker applications, good precision at hCG concentrations close to the upper limit of the reference range (i.e., good baseline security) is important, since relatively small elevations may be clinically significant, and between-run precision over time should be good enough to allow reliable identification of relatively small changes in hCG concentration in patients on long-term follow-up. (See below, section headed 'Quality assessment of hCG measurement'.) Studies relating to inter-individual biological variation of hCG have not yet been undertaken, probably because hCG concentrations in normal subjects are not measurable with most presently available routine methods.v'
STANDARDIZATION OF sec ASSAYS
The problems of standardization of heterogeneous hormones such as the gonadotrophins have been well reviewed." 67 Accepting that 'correct' results frequently cannot be defined for such analytes'" and that current knowledge of their structure and biological function is limited, there are, nevertheless, steps can be taken to improve method comparability. Clarifying what different methods are measuring, by reference to appropriate and universally accepted standards, provides an excellent starting point. Internationally recognized standards for hCG, hCGo: and hCGp are available from the National Institute for Biological Standards and Control (NIBSC, South Mimms, UK) and are listed in Table 4 . The present World Health Organization (WHO) standard for hCG, the 3rd International Standard (IS 75/537)69 [formerly known as the lst International Reference Preparation (IRP)], is a highly purified preparation from pregnancy urine with unitage based on earlier hCG standards calibrated by bioassays. Neither hCG(Y. (IRP 75/569) nor hCGp (IRP 75/551) has any known biological activity, so the assigned concentrations are expressed in arbitrary units. This makes comparison of concentrations of hCG!X, hCG/J and hCG very difficult, since the units of the first two molecules do not bear any relationship to those for hCG. As shown in Table 5 , by making some assumptions it is possible to convert concentrations of hCG and its subunits in U/L to approximate molar concentrations. While this allows some comparison of the extent to which different methods recognize these different species, the situation is far from satisfactory.
Most hCG methods currently available are calibrated in International Units (IU) of the 3rd International Standard (IS 75/537). Comparing results obtained with methods calibrated against the 3rd and the (previous) 2nd International Standards is difficult since the 2nd IS contained free subunits which were recognized to very different extents by different methods. The 3rd IS is itself now known to contain 10--20% nicked hCG, half of the nicks being found at a position different from those found in pregnancy urine, and its suitability as a standard has recently been Ann e{in Bio('hem 1998: 35 METHODOLOGY OF hCG ASSAYS hCG was measured by bioassays until the development in 1960 of a rapid and convenient haemagglutination inhibition method?" which rapidly replaced bioassay for use in pregnancy testing. Modern bioassays still provide scientifically valuable information about the biological function and properties of hCG and related molecules," and are clinically relevant as the original basis for standardization of hCG, as well as in the assessment of pharmaceutical preparations ofhCG. However, their routine use has been almost wholly supplanted, firstly by refined versions of the haemagglutination A,m CUn Biochem 1998: 35 inhibition method, and then by the much less labour-intensive immunoassays developed subsequently. The principles of the three assay methodologies will be considered briefly here.
Bioassays
In animal bioassay, preparations of hCG exhibit interstitial cell stimulating activity (ICSA),72.73 thyroid stimulating activity (TSA?4 and folliclestimulating activity (FSA).75 Several in vitro bioassays which exploit these biological activities have been widely used in recent years. Interaction of hCG with a receptor on the extracellular surface of a membrane effects a change on the intracellular surface. In both the gonad and the thyroid the critical transduction event is an alteration in the activity of adenyl cyclase, resulting in cyclic adenosine mono phosphate (cAMP) production. Measurement of cAMP generated in this way has been used for bioassays of both ICSA 72,73 and TSA.74 A major limitation of these in vitro assays for hCG, however, is their lack of analytical specificity, as hLH cross-reacts in these assays.
In vivo bioassays may measure changes in the weight of animal organs. The ventral rat prostate bioassay, for example, relies on a complex series of events: interaction of hCG with the Leydig cell LH receptor stimulates cAMP production which stimulates testosterone production and eventually, after a series of biochemical events in the prostate, results in an increase in prostate weight, which is then measured. Clearly, such assays are very complex in nature, variable in response, and require test animals. Their lack of analytical sensitivity also makes them impractical, and spurious results may be obtained due to variations in the metabolic clearance rates of hCG species 
Method specificity
The discrepancies observed could also reflect differing antibody specificities, but at least one of the antibodies employed in most current pregnancy kits is generally an anti-hCGp monoclonal antibody, which confers considerable specificity for the intact molecule. This allows measurement of hCG in the presence of hLH, and explains the high specificity of current pregnancy tests. Interestingly, although most tests do not appear to recognize hCGpcf,21 a major source of hCG immunoreactivity in pregnancy urine, the presence of variable amounts of hCGn might be responsible for method-related differences in results. 77 
Sensitivities and detection limits
In a recent study of ten pregnancy tests, detection limits (range 20-1000 U/L) were shown to be close to those claimed by the manufacturers." Methods employing immunochromatography or immunoenzymometry had the lowest detection limits (20-50 U/L), while latex agglutination and haem agglutination techniques were least sensitive (> 200 U/L for tube tests and > 500 U/L for slide tests). For individual urine specimens, some quite wide differences were observed in results obtained with different kits. These discrepancies may reflect the influence of different pH values or of variable salt concentrations, since high salt concentrations may inhibit immune reactions."
Qualitative methods (pregnancy tests) Principles
Qualitative detection of hCG is most appropriate when all that is required is a 'yes/no' test for pregnancy. Early bioassays used for pregnancy testing were replaced in 1960 by a haemagglutination inhibition method with a detection limit of 200300 U/L and an incubation time of 1·5 h. 70 This method has been refined, but the agglutination technique still forms the basis of numerous pregnancy testing kits now available 'over-the-counter'. These agglutination techniques can be very conveniently used by professionals and nonprofessionals with equal ease." More recently, enzyme-linked immunosorbent assay (ELISA) procedures have become available in a variety of forms (dipsticks, pots, tubes, etc.). Although details differ, the principles of these tests are broadly similar, and are illustrated in Fig. 3 . In a number of these tests, dyelabelled rather than enzyme-labelled antibodies arc now used, obviating the need for a colour developer (substrate) and thus simplifying the procedure.
present. Measuring human isoforms in assays that use animal receptors is also potentially disadvantageous, as misleading results may be obtained.
Application of modern techniques of molecular biology will almost certainly result in the development of in vitro bioassays that arc more practical, reliable, informative and less expensive." However, these assays are likely to remain primarily tools for the research laboratory.
allow detection of pregnancy 7-9 days after conception, when the hCG concentration is approximately 25-50 U (L. Further improvement in sensitivity would be likely to increase the risk of false positive results, as concentrations of hCG up to 9 U (L may occur in the serum of non-pregnant women, as well as in malignancy. Lower detection limits, while helpful in detecting ectopic pregnancy, also have the disadvantage of potentially diagnosing more early sub-clinical abortions as pregnancies.
Selecting the most appropriate detection limit is difficult. Pregnancy tests with a detection limit of 200 U (L are sensitive enough to diagnose pregnancy. However, it may cause confusion if a doctor were to use such a test, possibly obtaining a false negative result, when patients have access to home tests with detection limits of25-50 U(L. When used by lay people, pregnancy tests may not achieve the high clinical specificity and sensitivity achievable by trained technologists. When 11 home-use tests, previously confirmed by trained technologists to have 100% accuracy, were tested by a panel of 638 volunteers, 50% incorrectly evaluated the urine specimen they were given." This was attributed primarily to difficulty in interpretation of the instructions for reading the test. The authors concluded that such tests require rigorous analytical validation and preliminary evaluation by the potential user population.
Quantitative immunoassays Principles
In the last five years most routine laboratories have adopted commercially available hCG methods for the quantitative determination of hCG. Most of these methods are listed in the Kluwer Immunoassay Directoryi! which also gives comprehensive information about the principle, detection method and performance of each method. Table 6 summarizes these for nine commercially available methods. The principles and design of these radioimmunoassay (RIA) and immunoradiometric methods have been well described previously.P'F The type of label used has a considerable influence on achievable perforrnance.F Reagent limited assays usually employ radiolabels (most frequently 125I-labelled antigen) or enzyme labels (most frequently horseradish peroxidase or alkaline phosphatase). Although similar sensitivities are theoretically achievable with either detection system, in practice colorimetric assays rarely achieve the analytical sensitivity of RIA.
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Not only are colorimetric methods limited by the lower and upper limits of spectrophotometric measurement, but they are also more susceptible to interference and changes in assay conditions during the signal generation stage. However, if serum constituents are removed prior to the enzymatic reaction (as in the Bayer* Immuno I™ method) such problems can be minimized.
Some reagent excess assays use radiolabels, but methods with non-isotopic labels (enzymatic, fluorometric or luminometric) are increasingly being used, and these now form the majority method group for many analytes monitored by the UK National External Quality Assessment Schemes (UK NEQAS).K] Nonisotopic labels arc particularly well-suited to automation because of the optical detection methods required, as well as their long reagent shelf-life. Use of enzyme labels still limits the working range achievable, although this can be improved somewhat by use of enzyme amplification techniques. Further dramatic improvement is also possible by using the same enzyme labels with use of substrates that convert to fluorescent products. Fluorometric detection can improve sensitivity by at least an order of magnitude, since fluorescent compounds may be repeatedly stimulated to produce a signal in a short space of time, and this is employed in a number of methods including the Abbott IMx ™ and Abbott AxSYMTM methods. Direct fluorescence assays, using fluorophore labels instead of 125 1_ labels, are also available, for example in the Wallac DELFJA™ method. This method employs time-resolved rather than conventional fluorometry, much increasing the working range and virtually eliminating the interference from background fluorescence and quenching effects that can limit the sensitivity achievable by conventional fluorometric measurements.
Use of chemiluminescent labels, which emit light during the course of a chemical reaction, also avoids these problems, and forms the basis of the Ortho-Clinical Diagnostics Arnerlite" methods. Chemiluminescent methods may also utilize enzymes as labels, with chemiluminescent substrates. In practice, luminescent immunoassays can achieve much higher sensitivity than radioisotopic or fluorescent immunoassays. In a novel development, chemiluminescent reactions that lead to the emission of light can be initiated "Addresses of all manufacturers mentioned in the text are given in Appendix 2. ...
-.I
Ul W electrically rather than chemically, using electrochemiluminescent processes known to occur with numerous molecules, including compounds of ruthenium. This approach forms the basis of the Boehringer ElecSysTM methods, which may bring further improvement in assay detection limits and working ranges. The CIS Kryptor" system represents another major technological advance. The homogeneous TRACE™ methodology employed allows measurement of both large and small molecules without the need for separation of free and bound forms of the label, which is both complex and liable to introduce significant errors in immunoassays.
Properties of commercially available heG immunoassays Working range It is highly desirable that assays for hCG cover a relatively wide working range since hCG concentrations in physiological specimens may vary from < I U/L in healthy individuals to > 10 6 U/L in patients with advanced malignancy. The highest kit calibrator concentration in most non-competitive immunometric methods is 500 or 1000 U/L, so pregnancy specimens must usually be pre-diluted, as is also the case for serum samples from some cancer patients. Competitive RIAs tend to have somewhat narrower working ranges than immunometric methods, as would be predicted theoretically.P but the difference is perhaps not as marked as might be expected. Availability of sufficient appropriately constituted diluent is essential, and automatic dilution facilities are highly desirable. (See also later discussion of specimen volumes and hook effects.)
Sensitivities and detection limits
The definition of detection limit generally adopted by manufacturers is that concentration 2 SD above the mean of the 'zero' calibrator measurement values, representing the lowest measurable concentration of hCG that can be distinguished from zero. Values reported by manufacturers range from < 0·1 to 5·0 U/L, the higher limits generally being those for RIA methods, and, as would be predicted, lowest limits being those for methods employing luminometric detection. The experimental derivation of such data is of course important and necessitates study of individual kit inserts, since the matrix of the 'zero' calibrator is relevant. It has been recommended that, in order to reduce the effects of non-specific factors Ann Clin Biochem 1998: 35 present III pathological fluids (sometimes described as 'matrix' effects), a detection limit determined using assay buffer only should be at least fivefold lower than the clinical sensitivity or discrimination limit required." It would be useful if the minimum quantifiable concentration (defined as the lowest concentration for which a coefficient of variation of 20% can be achieved") was also specified in kit inserts, but this information is rarely presented.
Accuracy
Most manufacturers provide detailed recovery data obtained using pools of serum from normal male subjects to which known amounts of the working calibrator has been added; reported recoveries generally vary from 95 to 105%. In addition, some manufacturers (e.g. Baxter Diagnostics Inc) provide data showing recoveries obtained for specimens containing known added concentrations of hCG IS 75/537.
Many manufacturers also provide data comparing results for a new kit with those obtained using another commercially available method, sometimes terming this 'accuracy by correlation'. While such correlations provide some assurance that, in general, results obtained using each method will be comparable, they are not a substitute for a properly conducted experimental assessment of recovery. The limitations of method comparisons based on similar correlation data have recently been discussed. 84 • 85 Imprecision Kit inserts often include very useful information about the within-run and between-run performance achievable by the method at different concentrations of analyte. Naturally, care is required when comparing data from different manufacturers. While some manufacturers provide detailed precision data determined according to the recommendations of the NCCLS protocol." others provide much less comprehensive data. This makes between-method comparison of precision data quite difficult. Some manufacturers, for example, only provide data for pools of relatively high concentration similar number give no preCISIOn figures in the kit inserts. Fig 4 shows mean between-run preCISIOn figures for a number of intact and total hCG immunoassays. The graphs suggest that precision is generally satisfactory for all method types, with mean coefficients of variation often less than 6%, at concentrations of hCG greater than 50 UjL. However, precision is markedly poorer at lower concentrations. Few manufacturers provide data for pools of concentration similar to that of the highest calibrator (> 600 UjL), but where data are supplied coefficients of variation are encouragingly low. Data in Fig. 4(a) and (b) suggest that assay performance is independent of method type, although non-isotopic methods with fluorometric detection systems tend to have somewhat lower coefficients of variation. Interestingly, precision appears to be slightly better at low concentrations for methods measuring total hCG (hCG + hCGP) [ Fig. 4(b) ] compared with those measuring hCG only [ Fig. 4(a) ]. While it is obviously essential to look at precision data for individual methods, these graphs suggest that between-batch coefficients of variation of less than 6% should be reasonably readily achievable over much of the concentration range.
Linearity
Information related to linearity, i.e. parallelism on dilution, is provided in some kit inserts, which report experiments in which serum samples are assayed at serial dilutions. Documented linearity is good: generally when deviations from linearity are observed in routine practice, they are most often attributable to interfering substances which may be present in occasional specimens [see below].
Method specificity
The analytical specificity of any immunoassay depends on the specificity of the antibodies employed, and clear information about the specificity of a particular assay is important for its optimal clinical application. Early polyclonal antibodies prepared by immunization with intact hCG were generally highly cross-reactive with hLH. Following elucidation of the primary structures of hCG and LH, several groups used conjugates of the C-terminal peptide region to produce antisera that were highly specific for hCG, but these antibodies tended to be of relatively low affinity.
The advent of monoclonal antibodies has permitted the development of highly sensitive and specific procedures for measurement ofhCG, and allows the greatest versatility in defining assay specificity, as has been elegantly described.V Immunoassays with restricted specificities can be designed more readily using reagent excess rather than reagent limited methods, since the former require two antibodies, directed against two different epitopes on the antigen. However, dual antibody assays can be designed to have wider specificity, for example by using polyc1onal antisera against hCGp on one side of the sandwich. Since reagent limited methods depend mainly on the detection of one epitope, they frequently show broader specificity.
Cross-reactivity
witn other glycoprotein hormones. Specificity of anti-hCG antibodies is assessed by measuring reactivity with potentially cross-reacting substances, notably LH, FSH, TSH, and their subunits and fragments. Accurate quantification of crossreactivity is difficult. Ideally, completely pure antigens should be used in such studies. Such preparations are not yet readily available, but production of hormones and subunits by recombinant techniques should overcome this problem in the future. Cross-reactivities should also be measured at various antigen concentrations, as they may be concentration-dependent, particularly for polyclonal antisera. As has been recommended previously.P" conditions used for measuring and expressing the degree of cross-reactivity (ideally on the basis of molar concentrations when suitable standards are available) need to be defined.
Most manufacturers provide information about the cross-reactivity of their hCG assays with LH, FSH and TSH, although the lack of uniformity in how these data are derived can make comparison of methods somewhat difficult. While reported cross-reactivities are generally < 2% for all three pituitary hormones, it is not surprising, in view of the close structural similarity between the beta-subunits of hCG and LH, that cross-reactivity with LH in hCG assays is often 2-3 times higher than that of FSH or TSH. Even so, the concentrations of LH used to measure cross-reactivity are often much higher than those likely to be encountered physiologically, for example in post-menopausal women, and these cross-reactions are unlikely to cause problems in routine practice.
Recognition of other hCG-related molecules. It is always desirable that users of a method know
Ann Clin Biochem 1998: 35 what it is measuring, that is, the extent to which the different hCG-related molecules are recognized, particularly if there are method changes during patient follow-up. As yet, few hCG kit manufacturers provide comprehensive data about this, partly because of the difficulty of obtaining well-characterized preparations for such studies. Probably of greatest practical importance is whether or not a method recognizes hCGp. Although cross-reaction of hCGp in hCG assays is undesirable from a purely analytical point of view, since measurement of 'mixtures' is problematic.P for clinical use a method recognizing both hCG and hCG/3 may be most desirable if separate hCGp measurement is not available. Reactivity of both components may not be equimolar, as has been demonstrated in the UK NEQAS for hCG. 83 Recognition of hCGn is probably lower than that of intact hCG in some immunoassays, and this may also be the case for hCGpn, but whether this is clinically significant has yet to be established.
Differences in the recognition of different hCG-related molecules can undoubtedly cause considerable confusion when attempts are made to compare results obtained using different hCG methods for specimens containing more than one hCG-related species. The wide ranges of results observed on issuing specimens containing different hCG-related species through UK NEQAS illustrate this well (Table 7) . These differences may perhaps be less important when measuring hCG concentrations during normal pregnancy, as the serum concentrations of hCG/J tend to be analytically insignificant compared to those of hCG itself. However, for patients with tumours producing both hCG and hCG/J the apparent hCG concentration measured using an intact method may differ markedly from that measured using a total method. Different total methods may also give significantly different results for the same specimen, since few of these methods recognize hCG/J quantitatively. Socalled 'nicking' of hCG, or hCGp, which may affect their immunoreactivity significantly, can also result in dramatic differences in measured 'hCG' concentrations.P'F"?
Assay robustness
Discrepancies in results can be due to a number of other causes, 10 .911.91 some of which are listed in interferences) or to the method (exogenous interferences). Such errors can in theory affect all imrnunoassays, although particular analytes are more vulnerable to certain of them. The much increased use of immunometric methods means that problems associated with assay hooking (see below) and heterophilic antibodies are now much more relevant, since neither of these are likely to cause major difficulties in competitive RIAs. Factors potentially most likely to cause confusion or misinterpretation of hCG results include the presence in the specimen of cross-reacting substances, antireagent antibodies, or unexpectedly high concentrations of analyte (the high dose 'hook' effect).
Anti-reagent antibodies. Falsely high or low results may be obtained for patients' serum samples containing anti-immunoglobulin G (anti-IgG) antibodies capable of reacting with the antibodies used in the assay. Such heterophilic antibodies are very common." and it is assumed that the actual immunizing agent in most patients is bovine immunoglobulin absorbed from meat and milk."? The effect is generally eliminated by adding non-specific IgG (usually non-immune animal serum) to the assay mixture. Determining the amount required to ensure that interference in all patient serum samples will be eliminated is very difficult. Even when added IgG is incorporated in a method, usually at concentrations determined somewhat empirically, it is not possible to be certain that erroneous results will never be obtained, since individual human immune responses to animal IgG vary considerably. The same applies to the presence of human anti-mouse antibodies which are frequently induced, often at quite high concentrations, in cancer patients who have undergone treatment with mouse monoclonal antibodies, either for imaging or therapeutic purposes. While there are few reported cases of such interference in hCG assays resulting in inappropriate patient management, these are hazards which can potentially have very serious consequences. Little information about these effects is provided in kit inserts, although some manufacturers state that their method should not be used for specimens from patients who have received treatment with mouse monoclonal antibodies. Occasional distributions of specimens containing added human anti-mouse antibody by UK NEQAS over the last six years have demonstrated that a few hCG methods are at present vulnerable to interference from these antibodies, sometimes to an extent that could lead to possible misinterpretation of clinical results.P' Most methods are not affected but it is, nevertheless, important that laboratories be aware of the possibility of such interference, whatever method is used. Any results which do not fit with the clinical picture should always be examined critically.
Unfortunately, moderate interference is often most difficult to detect and may be potentially more dangerous than gross interferences for which discord between immunoassay results and the clinical picture is likely to provoke immediate further investigation." If interference from heterophilic antibodies is suspected, this can be readily investigated by determining whether the apparent hCG concentration changes on re-assaying the specimen at dilution or on adding further non-immune mouse serum to the reaction mixture, and also by measuring hCG using a different method (preferably RIA). Measurement of urinary hCG can also sometimes be helpful if falsely elevated serum hCG concentrations are suspected, since urine does not contain interfering antibodies. 
Type of error
Comments and examples relevant to the measurement of hCG
Endogenous interferences (arising from properties of the specimen)
Cross-reacting substances hCGp, giving different results depending on extent to which the method recognizes this species;" hLH, present in post-menopausal women and in patients with iatrogenic primary hypogonadism following chemotherapy.') Non-specific interference Rarely reported; has resulted in inappropriate chemotherapy being given to a seminoma patient." Decreased by minimizing ratio of specimen volume to total incubation volume, provided pipetting precision is not jeopardized.
N on -immunoreactive hormone isoforms
Anti-analyte antibodies Anti-reagent antibodies
Rheumatoid factor
High-dose hook effect Lipids, haemogloblin, paraproteins and other serum constituents
Iatrogenic causes
Not hitherto reported for hCG (although have been reported for hLH"); biosynthetic defects of hCG synthesis can yield false-negative hCG results, c.g, in ectopic pregnancy."
Anti-hCG antibodies may occur in patients treated with urinary hCG, e.g. during ovulation induction."
Heterophilic antibodies, present in up to 40% of normal individuals," and human anti-mouse antibodies, present in up to 70% of patients who have been treated with mouse monoclonal antibodies?" may bind to reagent antibodies to produce falsely high or low results. Inappropriate treatment may result."
Mostly IgM autoantibodies directed against a determinant in the Fc portion of the IgG molecule in patients with rheumatoid disease; their effect on hCG (and other) immunoassays is uncertain, with little documented information."
Failure to recognize extremely high levels of hCG can lead to misdiagnosis of potentially fatal but curable malignancy.'?'
Tend to be more of a problem in homogeneous assays so are not of major relevance to most hCG immunoassays.
Use of cannabis can transiently elevate serum hCG levels.""
Exogenous interferences (arising from equipment/assay system) Specimen carry-over Potentially a problem whenever very high concentration specimens assayed.
Contaminants affecting label detection
Heat-treatment of sera prior to assay
Blood collection tubes

Mis-sampling by automated analyser
Factors interfering with measurement of label, e.g. enzyme inhibitors in enzyme immunoassays, endogenous ftuorophores in fluoroimrnunoassays, radioactive contamination of specimens."
Heat treatment carried out to deplete serum complement components can result in major increase in concentrations of hCG:x and hCG{J.'112
Few published reports but differences in results between serum and EDTA or citrate plasma may be due to inhibition of complement activity by chelating agents. III)
Failure of mechanisms for level sensing or clot detection. hLH = Human luteinizing hormone; IgG = immunoglobulin G; EDTA =ethylenediaminetetraacetic acid.
High dose 'hook effect'. Two-site immunometric assays in which both capture and labelled antibody are added simultaneously are vulnerable to the high-dose hook effect. At very high analyte concentration, when amounts of both capture and labelled antibody become limiting, there is competition of free analyte and analyte bound to labelled antibody for the limited number of solid-phase antibody-binding sites,
Ann Clin Biochem 1998: 35 and under these conditions presence of higher concentrations of analyte will decrease rather than increase binding of label to solid phase. In the presence of sufficiently high analyte concentrations, erroneously low results (even within the reference range) may be obtained. The risk of reporting such an incorrectly normal result is greatest for analytes such as heG which cover wide concentration ranges.
Hook effects can be minimized by (a) using solid-phase antibodies of higher binding capacity, (b) by assaying specimens at two dilutions, or (c) by using sequential assays which include a wash step. None of these solutions is ideal. Reagent costs may increase markedly if solid-phase antibodies of higher capacity are used. Performing assays at two dilutions provides a simple and convenient means of ensuring that a specimen has not 'hooked', but even this is not without cost implications, requiring two determinations where one would otherwise suffice. Sequential ('two-step') assays require more time, thereby decreasing sample throughput in automated methods, but do prevent 'hooking'.
Many manufacturers quote a concentration above which their method may 'hook': these concentrations range from 4 x 10 4 to 2 X 10 6 U/L for hCG, confirming that hooking remains a real practical problem for hCG, an analyte for which concentrations in excess of 10 6 U/L are occasionally encountered in routine practice. The clinical consequence of failure to recognize extremely high concentrations can be severe.l'" emphasizing the importance of understanding the limitations of assay technology, particularly when interpreting the results of tumour marker measurements. As has previously been descri bed, 105 use of kinetic rate measurements can reduce the risk of failing to detect a hooked sample, and this approach has been adopted by some manufacturers of automated instruments.
Other relevant interferences. Many manufacturers provide comprehensive information about the possible effects of haemolysis, lipaemia and turbidity.!? although these would not necessarily be expected to present major problems in hCG immunoassays. Approximately 40% of hCG methods are stated to be unaffected by these potential interferences, many manufacturers indicating limiting concentrations above which they do not exclude interference. A further 38% of methods are said to be vulnerable without indicating the severity of the possible effect, while for 22% of methods no information is provided. Examination of individual kit inserts can provide helpful information about this.
Speed. convenience and cost
Methods selected for use by a laboratory should be those that enable the analytical system to be optimal for the pattern of workflow and the
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clinical requirements of the units served. Clinically, there may be some emergency specimens requiring urgent hCG measurement, while for both Down's screening and tumour marker applications it may be most efficient to measure both hCG and AFP simultaneously, either in parallel or using a dual analyte assay.
Many laboratories now use automated high capacity immunoanalysers, often with a 'stat' facility, permitting specimens to be processed and analysed virtually immediately on receipt, and greatly facilitating patient management where urgency is required, for example in ectopic pregnancy diagnosis. Where there are unavoidable delays in transporting specimens to the laboratories, side room testing using test kits may be more appropriate.
For other clinical applications, for example, in oncology units, assays provided two or three times weekly will be quite adequate, although it could be argued that it is more appropriate to centralize such testing in laboratories which can provide results within 24 h.
It is very difficult to compare the costs of hCG measurement by different methods, and no attempt will be made to do so here. For automated methods, costs will vary markedly depending on workload, range of analytes, and number of quality control (QC) specimens run. Operation in 'batch' mode rather than continuous or random access mode may save on calibration and QC costs. Manual methods will have lower consumables costs but increased staff costs, and impose batch mode operation which may constrain the flow of work through the laboratory.
SPECIMEN REQUIREMENTS Sample timing and handling
There is no convincing evidence of significant diurnal variation in hCG concentrations in plasma, serum or urine,106 so special timing of sample collection is generally unnecessary. However, the first early morning urine is often considered most appropriate for qualitative pregnancy testing. For quantitative testing in serum or plasma, it should be noted that if patients have been recumbent for more than I h the resulting plasma volume increase of 5--10% will cause a corresponding decrease in the apparent-concentration of hCG. All specimens should of course be treated with appropriate precautions to minimize infection.
Sample source and stability
Serum and plasma hCG is relatively stable in both serum and plasma, although the former is more often used. As for some other analytes, the chelating properties of citrate and ethylenediaminetetraacetic acid (EDTA) may have some influence on values obtained, but there is little documented evidence for this.? Serum or plasma are appropriate for most quantitative hCG methods. No preservatives are required, provided measurement is undertaken reasonably promptly and specimens are not kept for prolonged periods at room temperature.
An early study using a standard double antibody RIA for intact hCG and hCGIX demonstrated that both are stable in unfrozen serum or plasma stored at either 4°C or 22°C for up to 6 days.'?? A 20% decline in hCG values observed in whole blood stored at 22"C for 6 days was attributed to an increase in plasma volume caused by haemolysis. Stability of hCG at elevated temperatures, as well as during storage at -20 Q C and 4°C, has also been investigated. 10K hCG was stable in serum at +20°C for more than 87 h, and stability at 4°C was predicted to be of the order of 115 days. A 2·5% increase in hCGp was observed after ten freeze-thaw cycles, increasing to 10% after 25 cycles. hCG in liquid whole blood or whole blood filter paper spots was stable for at least 9 days at 4°C. At 25"C there was a twofold increase in hCG/J. The authors concluded that stability of hCG in serum is such that its collection and storage at room temperature or lower for reasonable lengths of time do not compromise the utility of measurement of hCGp in Down's syndrome screening. In a subsequent study.'?' known amounts of hCG were diluted in blood samples obtained from seven healthy male volunteers. There was a significant effect over time on hCG concentrations, depending on whether storage was at -70°C or room temperature.
Although under normal circumstances dissociation of the intact molecule is unlikely to be a problem, in certain conditions partial denaturation may occur, loosening the noncovalent interactions holding the IX-and /J-chains together. Such dissociation may occur in acidic conditions.P? in the presence of chaotropic agents.l'" or under the influence of heat treatment. 102 hCG and hCG/J, the decline in hCG may be compensated for by an increase in measured hCGfJ which can erroneously suggest that the hCG concentration has not changed; stability studies therefore must be undertaken with care.
Although further confirmation is probably required, the above observations indicate the need for care in defining specimen requirements in maternal serum screening programmes, in which specimens may spend varying lengths of time in transit to the screening centre, and in evaluating retrospective studies using stored specimens. Providers of external quality assessment (EQA) schemes and QC specimens also need to be aware of the potential effects of specimen instability.
Urine
Urine is most frequently used for pregnancy tests and for measurement of hCG/kf in cancer diagnoses. It can also be very useful for the longterm follow-up of hydatidiform mole patients. In the UK follow-up scheme, patients regularly send urine specimens by post to the central monitoring laboratory, where hCG concentrations are checked by RIA, providing an effective screening procedure which does not require the patient to visit either their general medical practitioner or hospital.w" For quantitative determinations, early morning urine should be used, and measurements corrected for variations in urinary volume rate by relating results to the creatinine concentration. When evaluating pregnancy test results, it is important to note that if a urine sample is very dilute the possibility of a false negative must be considered. Specimens from patients with ectopic pregnancy, conversely, may be very concentrated if the patient is in severe pain and is dehydrated, so caution must be exercised. In general, serum or plasma should be used for other quantitative measurements.
Amniotic fluid
Subunits are not formed in vitro in amniotic fluid, and their formation does not appear to be a problem on storage. Results of a study in which amniotic fluid specimens were stored at room temperature, 4°C or -20"C and then reassayed, indicated that the variation in results obtained is less than inter-assay variation, demonstrating the considerable molecular integrity of hCG under appropriate storage conditions. I I I The predominant form of hCGIX in amniotic fluid has been reported to be larger than hCGrx isolated by dissociation of hCG, and has been. suggested to be a hyper-glycosylated form of the subunit that is unable to combine with hCGfJ.lI2
Cerebrospinalfluid (CSF)
Measurement of hCG in CSF may be helpful when a primary intracranial tumour or cerebrospinal metastases from an hCG-producing tumour are suspected.'!' Determining the ratio of hCG in CSF to that in serum may be helpful: the normal CSF to serum ratio is I: 60, higher levels of hCG in CSF being suggestive of metastases. I 13 Elevated concentrations have also been reported in CSF from patients with craniopharyngiomas.'!"
Ascitic fluid Measurement of hCG in ascitic fluid can be used in the diagnosis of ectopic pregnancy and intraabdominal malignancy.7.115 Levels of immunoreactive hCG have also been reported to be significantly elevated in malignant ascitic fluid from patients with ovarian, endometrial and cervical malignancies as compared with concentrations in benign ascitic fluids.I'" It has been suggested that hCG is as useful a parameter as total protein for the differentiation of malignancy-related and non-malignant ascites.!'?
Cystfluid
Total hCG immunoreactivity has been reported to be present in cyst fluid from craniopharyngioma patientsl!" and from women with gynaecological malignancies. I 16 Specimen volume Kit inserts usually state the minimum specimen volume required for assay: these vary from 5-200/-lL. Some care is needed when assessing these figures. For some automated instruments there is a significant 'dead volume' which must be taken into account, but which may be constant however many different analytes are measured on the specimen. For example, the DPC Immulite" method requires only 5 /-lL for a single hCG determination, but the same cup should contain at least 100 ul, more than the total volume required for all tests to be performed on the sample. Where specimens routinely require dilution (as for many pregnancy samples) this also needs consideration. However, unless paediatric specimens are frequently assayed, specimen volume is unlikely to be a major issue.
Analysis of hCG 481
Specimen dilution As mentioned above, hCG concentrations routinely encountered range over several orders of magnitude. Commercial assays are generally optimized for high analytical sensitivity and are linear only up to 500 or 1000 UfL, so dilution will usually be required. Accuracy of pipetting devices must be ensured by the laboratory if automated dilution is not available on the analyser, while the accuracy of automated onboard dilution should also occasionally be independently verified.
QUALITY ASSESSMENT OF hCG MEASUREMENT
Internal quality control of hCG assays Internal quality control (IQC) comprises the steps taken to ensure that test results meet defined quality requirements. It is a complex process, and has been fully described elsewhere. [118] [119] [120] CLlA as within ± 3 SD of the target value.
Factors to consider when implementing a successful IQC policy are generally similar to those for other analytes, but the following are of particular importance for hCG:
Ensuring IQC materials closely resemble authentic patient sera. Lyophilized IQC serum samples do not always behave identically to patient samples and error may be introduced on reconstitution. Commercial IQC materials usually have a serum matrix (although controls supplied by the manufacturer may not) but may be supplemented with purified hCG which differs from endogenous hCG. In general, it is inadvisable to rely exclusively on QC materials supplied with the kit, and an authentic serum matrix control from an independent source should be included. Heat treatment of specimens for hCG must always be avoided.
Choosing IQC concentrations appropriate to the clinical applications. For hCG, negative and low positive controls need to be included, but there is also a requirement to cover the broader concentration range. When screening for fetal chromosomal abnormalities, pools with hCG concentrations in the range of second trimester specimens must be included.
Assessing assay interference. Occasional checking for interferences from heterophilic and other antibodies, high dose hook effects, clotting agents in blood collection tubes, and preservatives added to EQA specimens is desirable, as method characteristics can change with changes in formulation of kit reagents.
External quality assessment of beG assays EQA schemes can provide objective, albeit retrospective, information about how well individual participating laboratories are measuring a given analyte, while also offering unique insight into how methods are performing in the field. 88 Standard), as should their stability (e.g. by repeated distribution of the same pool).
Key characteristics of some of the currently available EQA schemes are summarized in Table  9 . Information available from different schemes is influenced by a number of factors, including specimen type and frequency, data analysis and method mix. The necessity of ensuring that EQA specimens are appropriate will be given added impetus on the introduction of the proposed European In Vitro Diagnostics Directive, 125 which promotes a role for EQA schemes in wider monitoring of the performance of diagnostic kits. It is interesting to note that broadly similar coefficients of variation are reported across schemes for hCG (Table 9 ) despite differences in scheme design. The proportion of participants using methods measuring hCG as compared to hCG + hCGfJ is also remarkably similar in different schemes.
When designing overall quality goals for a laboratory and deciding how best to achieve them, it is clear that IQC and EQA are closely related and complementary activities, which are usefully considered together; both also contribute to clinical audit of the laboratory service. Participating in an EQA scheme which provides occasional assessment of potential assay interferences or baseline security, for example, may make it unnecessary to include this as part of the laboratory's IQe. Interpretative exercises and surveys are also an important feature of some EQA schemes, allowing participants to compare their practice (e.g. reference ranges, provision of comments and cumulative reports) with that of others.P" These exercises can contribute to continuing audit of the overall laboratory process, and ultimately may encourage improved consensus about how hCG measurements should be used.
FUTURE DEVELOPMENTS
Measurement of hCG forms an important part of the diagnostic repertoire, both in pregnancy and in malignancy, and advances in immunoassay automation have brought the test within reach of most clinical chemistry laboratories. Knowledge of the crystal structure of hCG, which now allows precise identification of the relative locations of regions of the hormone's surface, together with the considerable epitope mapping data already available, will promote better understanding of its complex biological • Dipstick or home pregnancy tests are adequate for routine pregnancy diagnosis, and are positive at the time of the missed period. • Quantitative serum hCG results are required for early pregnancy monitoring, particularly for ectopic pregnancies, when results should be available within a maximum of 24h. Assays recognizing hCG or hCG + hCGp are satisfactory. • Measurement of hCG, hCG + hCGp, or hCGp forms an important part of all biochemical pre-natal screening programmes for Down's syndrome. High precision and rapid reporting of results are important. If methods measuring hCG/I are used, specimen stability during transit to the laboratory should be ensured.
• In choriocarcinoma, testicular and germ cell malignancies, measurement of hCG + hCG/I is desirable as some cancers may produce only hCGp, which an assay for hCG would miss. Rising levels should be confirmed by repeat analyses. A normal result never excludes malignancy or recurrence. • Measurement of serum hCGp or urinary hCGp core fraction may become important in non-trophoblastic tumours, but their clinical utility has yet to be established.
Analytical requirements of hCG assays
• Method specificity should be well-documented, since this may have important implications if serial hCG levels for a patient are determined in different laboratories. • A relatively wide working range is desirable as hCG concentrations may vary by as much as six orders of magnitude. For automated assays, on-board dilution facilities are very helpful. • Detection limits of 2 U/L are desirable for tumour marker and pregnancy applications, although 5 U/L may be adequate. Good baseline security is essential when using hCG as a tumour marker, as relatively small elevations may be of clinical significance. • Between-run coefficients of variation of < 6% should be achieved. Long-term 'stability' of hCG assays is extremely important for both Down's syndrome screening and tumour marker applications. • The possibility of misleading results due to assay interferences (e.g. cross-reacting substances, high dose 'hooking') must be recognized. • Assay performance must be systematically monitored in internal quality control and external quality assessment programmes.
functions. This, together with the availability of improved and well-characterized reference preparations, should permit definition of the antibody specificities of most relevance in given clinical situations. If this knowledge can be combined with use of antibody engineering to produce monoclonal antibodies of defined specificity, and with advances in immunoassay methods and automation (e.g. array-based multi-analyte binding assays), significant progress in the measurement of hCG-related species may be expected in the next decade. The benefits of these developments include greater commutability of results to facilitate improved guidelines, at local and international levels, for the appropriate use of these important tests.
SUMMARY
Study of the glycoprotein hormones, including hCG, is complex and evolving, and has benefited from recent major advances in analytical technology and molecular biology.
It is important to be aware of the effect that these technological advances have, both on the analytical and the clinical requirements for provision of a diagnostic service for hCG. Some aspects of particular relevance are summarized in Table 10 .
response expected from hCGfJ when measured in an assay recognizing hCG and hCGfJ on an equimolar basis, it is necessary to consider unitage in terms of molar equivalence, as illustrated below. and the response expected from I U of hCGfJ will be approximately 15,5 times greater than that from I U of hCG.
APPENDIX 2
Contact addresses for suppliers Where specific suppliers have been mentioned in this review, their products have been selected solely because they illustrate the points being made. Their inclusion is not intended in any way to constitute a recommendation or otherwise. 
Suppliers of assays for hCG:
